Clinical Trials in Tennessee

Showing 12081-12100 of 20,239 trials

A Phase 1b Open Label, Dose Escalation Study of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Melanoma

NCT01826448

The purpose of this research study is to test the safety of an investigational new drug called PLX3397 when used in combination with Vemurafenib (Zelboraf™) at different dose levels. Vemurafenib has been approved by the United States Food and Drug Administration (FDA)/European Medicines Agency (EMA) for the treatment of a specific category of unresectable or metastatic melanoma.

V600-mutated BRAF Unresectable MelanomaV600-mutated BRAF Metastatic MelanomaStage III or Stage IV Metastatic Melanoma That Has Not Been Previously Treated With a Selective BRAF Inhibitor

Daiichi Sankyo13 participantsStarted Nov 2013

Los Angeles, California, United States • Aurora, Colorado, United States • Nashville, Tennessee, United States +3 more locations

COMPLETEDPhase 329 miles

Andecaliximab With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

NCT02545504

The primary objective of this study is to compare the efficacy of andecaliximab (GS-5745) versus placebo in combination with modified fluorouracil (5-FU), leucovorin (LV), and oxaliplatin (OXA) (mFOLFOX6) as measured by overall survival.

Gastric Adenocarcinoma

Gilead Sciences432 participantsStarted Oct 2015

La Jolla, California, United States • Los Angeles, California, United States • Los Angeles, California, United States +131 more locations

A Phase 1b Open Label, Dose Escalation Study of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Melanoma

Andecaliximab With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Find Trials by Condition in Tennessee

A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)

A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast Cancer

CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC)

Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer

Immunotherapy Study for Surgically Resected Pancreatic Cancer

ENABLE: CHF-PC (Comprehensive Heartcare For Patients and Caregivers)

Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer

Selinexor in Combination With Fludarabine and Cytarabine in Patients With Refractory or Relapsed Acute Myeloid Leukemia

Safety Study of ECO Conversion System For Red Blood Cells.

Double-blind Placebo-controlled Trial of Generic Clindamycin/Benzoyl Peroxide Gel Versus Onexton Gel in Acne Vulgaris

High-Intensity Focused Electromagnetic (HIFEM) Field Device in Women After Childbirth

Dupilumab As An Adjunct For Subcutaneous Grass Immunotherapy

Vaccine Study for Surgically Resected Pancreatic Cancer

Transvenous Lead Removal Post-Market Clinical Study

Non-invasive Buttock Lifting Induced by Magnetic Device - Multicentric Study

VAL-1221 Delivered Intravenously in Ambulatory and Ventilator-free Participants With Late-Onset Pompe Disease

Alternative Dosing for CRLX101(NLG207) Alone, With Avastin and With mFOLFOX6 in Advanced Solid Tumors

A Study of LY3295668 Erbumine in Participants With Breast Cancer That Has Spread to Other Parts of the Body